ESTRO 2025 - Abstract Book

S1848

Clinical – Upper GI

ESTRO 2025

Conclusion:

The definition and staging of patients with oligometastatic esophagogastric cancer by intercontinental key opinion leaders reached fewer consensus compared to previous European consensus. As was the case in the European study, high practice variation in the recommended treatment remained.

Keywords: Oligometastatic Intercontinental Consensus

References: 1.

Liu Q, Chen J, Lin Y, et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. The Lancet Gastroenterology & Hepatology . 2023;doi:10.1016/S2468-1253(23)00316-3 2. Al-Batran SE, Goetze TO, Mueller DW, et al. The RENAISSANCE (AIO-FLOT5) trial: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer . 2017;17(1)doi:10.1186/s12885-017-3918-9

3909

Mini-Oral Nationwide photon radiotherapy planning study for oesophageal cancer

Sabine Visser 1 , Noor A. Panneman 1 , Maaike Berbée 2 , Mira Kijk in de Vegte - Oortwijn 3 , Maaike de Kroon 4 , Gert J. Meijer 5 , Karen J. Neelis 6 , Vera Oppedijk 7 , Peter S.N. van Rossum 8 , Heidi Rütten 9 , Tom Rozema 10 , Maurice van der Sangen 11 , Francine E.M. Voncken 12 , Paul Jeene 13 , Christina T. Muijs 1 1 Radiotherapy, UMCG, Groningen, Netherlands. 2 Radiotherapy, MAASTRO, Maastricht, Netherlands. 3 Radiotherapy, Isala, Zwolle, Netherlands. 4 Radiotherapy, ZRTI, Vlissingen, Netherlands. 5 Radiotherapy, UMCU, Utrecht, Netherlands. 6 Radiotherapy, LUMC, Leiden, Netherlands. 7 Radiotherapy, RIF, Leeuwarden, Netherlands. 8 Radiotherapy, AUMC, Amsterdam, Netherlands. 9 Radiotherapy, Radboud, Nijmegen, Netherlands. 10 Radiotherapy, Instituut Verbeeten, Tilburg, Netherlands. 11 Radiotherapy, Catharina ziekenhuis, Eindhoven, Netherlands. 12 Radiotherapy, NKI, Amsterdam, Netherlands. 13 Radiotherapy, Radiotherapiegroep, Arnhem, Netherlands Purpose/Objective: In radiotherapy for oesophageal cancer (EC), the goal is to deliver the prescribed dose to the target while minimising exposure to nearby organs-at-risk (OARs), particularly the heart and lungs. Traditionally, lung dose reduction was prioritised, but recent studies highlight the need to limit heart dose as well. In photon-based therapy, reducing